Activation of mTOR is a negative regulator in the process of autophagy, so the administration of mTOR inhibitors conducts an enhancement in both the inhibition to mTOR signaling pathway and the synergize cytotoxicity on RCC cells, thereby begetting the death of autophagic cells that modulate kinase-dependent proteins [13, 14]. The gene discussed is MTOR; the disease is renal cell adenocarcinoma.